India to Malta: Amphotericin Export Trade Route

To import finished pharmaceutical formulations containing Amphotericin into Malta, compliance with the European Union's regulatory framework is mandatory. The European Medicines Agency (EMA) oversees the authorization of medicinal products within the EU, while Malta's national competent authority, the Medicines Authority, implements these regulations locally.

Marketing Authorization: Before importation, a Marketing Authorization (MA) must be obtained for the specific Amphotericin formulation. Applicants are required to submit a comprehensive dossier in the Common Technical Document (CTD) or electronic Common Technical Document (eCTD) format. This dossier should encompass quality, safety, and efficacy data. The evaluation process typically spans 210 days, excluding any clock stops for additional information requests. Fees for product registration vary; applicants should consult the Medicines Authority for the most current fee structure.

Manufacturing and Importation License: Entities involved in the importation of medicinal products into Malta must possess a Manufacturing and Importation Authorization (MIA). This license ensures that imported products meet EU Good Manufacturing Practice (GMP) standards. The application process involves submitting detailed information about the premises, equipment, and quality systems in place. The Medicines Authority conducts inspections to verify compliance before granting the license.

GMP Inspection Requirements: Indian manufacturing facilities producing Amphotericin formulations intended for the Maltese market must comply with EU GMP standards. The Medicines Authority, in collaboration with the EMA, conducts GMP inspections to assess compliance. These inspections are risk-based and may be triggered by initial applications, routine surveillance, or specific concerns. Non-compliance can result in the refusal or suspension of the MA or MIA.

Indian pharmaceutical manufacturers exporting Amphotericin formulations to Malta are required to adhere to EU GMP standards. This compliance ensures that products are consistently produced and controlled to the quality standards appropriate for their intended use.

GMP Certification: Manufacturers must obtain GMP certification from an EU competent authority. This involves a thorough inspection of the manufacturing facilities to ensure adherence to GMP guidelines. The certification is a prerequisite for the approval of the MA and MIA applications.

Approved Indian Facilities: The EudraGMDP database maintains a list of manufacturing sites that have been inspected and found compliant with EU GMP standards. Indian facilities intending to export to Malta should ensure their inclusion in this database.

Recent Inspections and Regulatory Actions: In June 2024, the Medicines Authority issued a Statement of Non-Compliance with GMP for Akriti Pharmaceuticals, an Indian manufacturer. The inspection revealed critical deficiencies, including risks of cross-contamination, leading to the suspension of their GMP certification. This action underscores the importance of maintaining stringent quality standards to avoid regulatory repercussions.

Several regulatory developments between 2024 and 2026 have impacted Indian pharmaceutical exports to Malta:

Revision of India's GMP Regulations: In January 2024, India's Ministry of Health revised its GMP regulations to align more closely with global standards, including those of the World Health Organization (WHO). The revisions introduced a Pharmaceutical Quality System (PQS), Quality Risk Management (QRM), and Product Quality Review (PQR). These enhancements aim to improve the quality of pharmaceutical products and facilitate smoother exports to markets like Malta.

EU GMP Annex Revisions: In February 2026, the EMA initiated consultations to revise Annex 15 of the EU GMP guidelines, focusing on qualification and validation processes. The proposed changes aim to extend the scope to active substance manufacturers and incorporate updated quality risk management principles. Indian exporters should monitor these developments to ensure ongoing compliance.

Non-Compliance Reports: In March 2024, the Medicines Authority issued a non-compliance report for an Indian pharmaceutical company due to cross-contamination risks identified during inspections. This highlights the critical importance of adhering to GMP standards to maintain market access.

Staying informed about these regulatory changes and ensuring compliance is essential for Indian manufacturers aiming to export Amphotericin formulations to Malta.

As of 2025, Malta's healthcare expenditure was approximately €1.2 billion, representing about 9% of its GDP. The country has a universal healthcare system, ensuring comprehensive access to medical treatments for its population of around 514,000. The aging demographic, with over 20% of residents aged 65 and above, contributes to increased demand for antifungal medications like Amphotericin, commonly used to treat systemic fungal infections prevalent among immunocompromised individuals.

Malta primarily relies on imports for its pharmaceutical needs, including Amphotericin formulations, due to limited domestic manufacturing capabilities. In 2025, the country imported finished pharmaceutical formulations containing Amphotericin valued at $2.6 million from India, accounting for 3% of India's total exports of such formulations. The primary importer was Tillomed Malta Ltd, with purchases totaling $2.3 million.

Malta imposes a 0% import duty on pharmaceutical products classified under HS code 30049029, which includes finished formulations containing Amphotericin. Additionally, these products are subject to a Value Added Tax (VAT) of 18%. There are no preferential trade agreements between India and Malta that further affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on these imports.

India is a significant supplier of Amphotericin formulations to Malta, with exports totaling $2.6 million in 2025. While specific data on other supplying countries is limited, European Union manufacturers also contribute to Malta's pharmaceutical imports. India's competitive pricing and established pharmaceutical industry make it a preferred source for these formulations. For instance, the average import price for Terbinafine 250mg tablets, another antifungal medication, was $1.48 per unit in Malta, indicating competitive pricing from Indian exporters.

India has solidified its position as a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines as of 2024. This dominance is underpinned by a robust manufacturing infrastructure, with over 60,000 generic drugs produced across 60 therapeutic categories. The country boasts 752 FDA-approved facilities, 2,050 WHO-GMP-certified plants, and 286 EDQM-approved sites, ensuring compliance with stringent international quality standards.

The cost-effectiveness of India's pharmaceutical production is a significant advantage. Factors such as competitive land rates, affordable utilities, and lower machinery costs contribute to reduced manufacturing expenses. This economic efficiency enables Indian manufacturers to offer Amphotericin formulations at prices that are competitive on the global market.

Furthermore, India's extensive experience in producing finished dosage forms, including tablets, capsules, syrups, and injections, ensures a reliable supply of high-quality Amphotericin formulations. The country's commitment to maintaining and enhancing manufacturing standards positions it as a preferred source for these essential medications.

When comparing Amphotericin formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian manufacturers leverage cost-effective production methods to offer Amphotericin formulations at competitive prices. While specific pricing data for 2024-2025 is not readily available, India's overall pharmaceutical exports have been growing at a rate nearly double the global average, indicating strong market competitiveness.

• Quality Perception: India's pharmaceutical industry is recognized for its adherence to international quality standards, with a significant number of FDA-approved and WHO-GMP-certified facilities. This compliance ensures that Amphotericin formulations meet the stringent requirements of global markets.

• Regulatory Acceptance in Malta: Malta, as part of the EU, requires pharmaceutical imports to comply with EU regulations. Indian manufacturers with EDQM-approved facilities are well-positioned to meet these standards, facilitating smoother regulatory acceptance.

• Supply Reliability Track Record: India's pharmaceutical sector has demonstrated a strong track record in supplying generic medicines globally, including to highly regulated markets. The country's extensive manufacturing capacity and experience contribute to a reliable supply chain for Amphotericin formulations.

India's pharmaceutical manufacturing capacity is substantial, with over 60,000 generic drugs produced across 60 therapeutic categories. The country's infrastructure includes numerous facilities capable of producing finished dosage forms, such as tablets, capsules, syrups, and injections, ensuring a steady supply of Amphotericin formulations.

Packaging and cold chain capabilities are critical for maintaining the efficacy of pharmaceutical products. Indian manufacturers have invested in advanced packaging technologies and cold chain logistics to meet international standards, ensuring the safe and effective delivery of Amphotericin formulations.

Regarding regulatory compliance, Indian pharmaceutical companies have made significant strides. Instances of FDA Official Action Indicated (OAI) have decreased by 50% over the past decade, reflecting improved adherence to regulatory requirements.

While specific data on capacity constraints or expansion plans for Amphotericin formulations are not available, the overall growth of India's pharmaceutical sector suggests a commitment to scaling production capabilities to meet global demand.

For buyers in Malta seeking to source Amphotericin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amphotericin formulations.

• Minimum Order Quantities (MOQs): Indian manufacturers may have varying MOQs. It's advisable to negotiate terms that align with your procurement needs while considering the manufacturers' production capacities.

• Payment Terms: Common payment terms in India-Malta pharmaceutical trade include letters of credit (LC) and advance payments. Establish clear payment agreements to facilitate smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory certifications (e.g., FDA, WHO-GMP, EDQM), and assessment of quality control systems to ensure compliance with EU standards.

• Regulatory Compliance: Ensure that selected suppliers have a proven track record of regulatory compliance and can provide the necessary documentation to meet Malta's import requirements.

By implementing these strategies, buyers in Malta can establish a reliable and cost-effective supply chain for Amphotericin formulations sourced from India.

Before engaging with Indian manufacturers for Amphotericin formulations, Malta-based buyers should adhere to the following pre-qualification steps:

When sourcing Amphotericin formulations from Indian manufacturers, Malta buyers should request the following documents:

When evaluating Indian suppliers for Amphotericin formulations, be vigilant for the following warning signs:

To ensure consistent quality and compliance, Malta buyers should implement the following audit and monitoring procedures:

Cost Estimates and Timeline:

• Audit Visits to India:
• Plan for a 3-5 day on-site audit, with an estimated cost of $10,000 to $15,000 USD, covering travel, accommodation, and auditor fees.

• Remote Monitoring:
• Implement quarterly virtual audits, with each session costing approximately $2,000 to $3,000 USD.

By adhering to these guidelines, Malta buyers can ensure the selection of reliable Indian suppliers for Amphotericin formulations, maintaining product quality and regulatory compliance.